ReviewCancers2023
Current Understanding of
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.British journal of haematology · 2026Article
- DDX41-Mutated AML: A Case Report and Perspectives.JCO precision oncology · 2026Article
- Clinical and Molecular Spectrum ofJournal of clinical medicine · 2025Article
- Genomic variation in DDX41 identified through clinical sequencing.British journal of haematology · 2025Article
- Clinical Outcome and Molecular Profile in Patients withHematology reports · 2025Article
- Biallelic germline DDX41 variants in a patient with bone dysplasia, ichthyosis, and dysmorphic features.Human genetics · 2024Article
- Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia.NPJ precision oncology · 2024Article
- DDX41: exploring the roles of a versatile helicase.Biochemical Society transactions · 2024Review
- A scATAC-seq atlas of stasis zone in rat skin burn injury wound process.Frontiers in cell and developmental biology · 2024Article
- Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.American journal of hematology · 2023Article
- Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The DEAD-box RNA helicase 41 gene,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.